


REMARKS

Applicants are providing the following amended and new claims for further consideration. Support for amended claim 14 can be found at page 52. Support for new claims 86 and 87 derive from original claims 1 and 7, respectively. Support for new claim 88 can be found at page 79, line 24.

The Examiner is invited to contact the undersigned agent at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI
600 Congress Avenue
Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 18, 2003

APPENDIX A: Marked Up Copy of Amended Claims

1. (Twice amended) A peptide that targets a tumor cell, wherein said peptide comprises HN-1, (a variant of HN-1, or a HN-1 related peptide) [and said peptide is internalized by said tumor cell].
7. (Twice amended) A composition comprising:
 - a) a drug; and
 - b) a peptide that targets a tumor cell, wherein said peptide comprises HN-1, a variant of HN-1, or a HN-1 related peptide [and said peptide is internalized by said tumor cell].
14. (Amended) The composition of claim 7, wherein said drug is [Taxol] a plant alkyloid.
broadest scope
86. (New) The peptide of claim 1, wherein said peptide is internalized by said tumor cell.
87. (New) The composition of claim 7, wherein said peptide is internalized by said tumor cell.
88. (New) The composition of claim 14, wherein said plant alkyloid is paclitaxel.

APPENDIX B: Clean Copy of Pending Claims (Unofficial)

1. (Twice amended) A peptide that targets a tumor cell, wherein said peptide comprises HN-1, a variant of HN-1, or a HN-1 related peptide.
2. The peptide of claim 1, comprising SEQ ID NO:1.
3. The peptide of claim 1, consisting of SEQ ID NO:1.
7. (Twice amended) A composition comprising:
 - a) a drug; and
 - b) a peptide that targets a tumor cell, wherein said peptide comprises HN-1, a variant of HN-1, or a HN-1 related peptide.) *Markus*
8. The composition of claim 7, wherein said peptide comprises SEQ ID NO:1.
9. The composition of claim 7, wherein said peptide consists of SEQ ID NO:1.
10. The composition of claim 7, wherein said drug is a chemotherapeutic agent.
11. The composition of claim 7, wherein said drug is a cytotoxic agent.
12. The composition of claim 7, wherein said drug is an apoptotic agent.
13. The composition of claim 7, wherein said drug is a DNA-damaging agent.
14. (Amended) The composition of claim 7, wherein said drug is paclitaxel.
15. The composition of claim 7, wherein said drug is cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, transplatin, 5-fluorouracil, vincristine, vinblastine or methotrexate.
86. (New) The peptide of claim 1, wherein said peptide is internalized by said tumor cell.
87. (New) The composition of claim 7, wherein said peptide is internalized by said tumor cell.
88. (New) The composition of claim 14, wherein said plant alkyloloid is paclitaxel.